
Autonomix is focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. Nasdaq: $AMIX
The Woodlands, TX
Joined September 2023
- Tweets567
- Following132
- Followers297
- Likes34
“We believe the ability to identify, target and verify the effects of nerve-targeted treatment represents an important opportunity to advance neural sensing-guided procedures,” said Brad Hauser, President and Chief Executive Officer of Autonomix. Read more: bit.ly/48NNaO5 $AMIX
Autonomix's presentation today at the 2026 @TCTConference showcased its “Sense. Treat. Verify.” approach to neural sensing, targeted ablation and intra-procedure feedback. Learn more about the early preclinical evidence highlighted at #TCT2026: bit.ly/48NNaO5 $AMIX
1
1
120
$AMIX presented today at the 2026 Annual Scientific @TCTConference, showcasing its investigational transvascular precision-guided technology and early preclinical evidence supporting its approach to neural sensing and targeted intervention. bit.ly/48NNaO5 #TCT2026
1
81
“This latest patent further strengthens the intellectual property foundation supporting our proprietary sensing technology and reinforces our commitment to advancing precision nerve-targeted interventions,” commented Brad Hauser, CEO. Read more: bit.ly/4kD9EIQ $AMIX
12
2
220
Autonomix announced the issuance of U.S. Patent No. 12,793,841, “Medical Devices With Circuitry For Capturing And Processing Physiological Signals,” further strengthening $AMIX's IP portfolio around its proprietary catheter-based sensing technology. bit.ly/4kD9EIQ
2
181
Brad Hauser, Chief Executive Officer of Autonomix Medical, comments on the issuance of a Canadian patent covering Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies: bit.ly/4xTQyB9 $AMIX
1
245
Autonomix's new Canadian patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall. Read more: bit.ly/4xTQyB9 $AMIX
1
194
Autonomix today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, further reinforcing the Company’s transvascular intervention platform across multiple nerve-targeted therapies. Read more: bit.ly/4y8N664 $AMIX
1
171
“This FDA interaction gives us greater clarity on the work required to pursue an initial U.S. clearance and represents a significant milestone in advancing our proprietary technology toward the U.S. market,” said Brad Hauser, $AMIX CEO. bit.ly/4hUwppN
1
128
Autonomix's FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning $AMIX for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months. bit.ly/4hUwppN
1
115
Autonomix today announced the successful completion of a pre-submission meeting with the U.S. FDA regarding $AMIX's recently announced standalone transvascular sensing platform, which is designed to detect and differentiate faint biological signals. bit.ly/4hUwppN
2
94
"This European patent represents another important step in expanding our global intellectual property footprint," said Brad Hauser, Chief Executive Officer of Autonomix. Read more about Autonomix's international intellectual property portfolio: bit.ly/47gbqrl $AMIX
1
76
Autonomix's new European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio. Learn more about the patent: bit.ly/47gbqrl $AMIX
1
75
Autonomix has been granted European Patent No. EP 4 233 700 B1, further expanding the Company’s international IP portfolio and strengthening protection for technologies supporting autonomic nervous system assessment and precision neuromodulation. bit.ly/47gbqrl $AMIX
1
73
“I am excited to join Autonomix as a Board Member at an important stage in the Company’s development,” said Sandra Cohen Kalter. Read more about her recent appointment: bit.ly/4xZXdLa $AMIX
1
109
“Sandy brings an extraordinary level of MedTech experience, particularly from her time at Medtronic, where she was at the intersection of regulatory strategy, clinical development, technology evaluation and corporate transactions,” said Walter Klemp bit.ly/4xZXdLa $AMIX
2
296
Autonomix today announced the appointment of Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic plc (Medtronic) as a Board Member. Read more: bit.ly/4xrA3fm $AMIX
1
94
Autonomix's abstracts for poster presentation at the upcoming @cirsesociety 2026 Annual Congress highlight the potential of Autonomix’s transvascular technology across pain management and nervous system mapping. For presentation details, visit: bit.ly/4xwg6VD #CIRSE2026 $AMIX
3
218

